drugset / Trial / NCT05812014
Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older
Phase 3
Unknown
9800 enrolled
AIM Vaccine Co., Ltd.
LiveRNA Therapeutics Inc. · collabNingbo Rongan Biological Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a multi-center, randomized, blinded, placebo-controlled, phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 bivalent mRNA vaccine (LVRNA021) as booster in participants aged 18 years and older who completed primary/1 booster dose(s) of SARS-CoV-2 vaccination.
Timeline
- Start
- 2023-03-25
- Primary completion
- 2024-03
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVRNA021 | Messenger RNA (mRNA) | 100 ug | Intramuscular |